bombesin receptor

GRP (14-27) (human, porcine, canine) serves as a ligand for bombesin receptors, with specific binding inhibited by GTP and GDP, but unaffected by GMP [1].

[D-Phe12,Leu14]-Bombesin acetate inhibits bombesin-stimulated secretion.

BA 1 acetate is a potent bombesin receptor agonist (IC50 values are 0.26, 1.55 and 2.52 nM for BB1, BB2 and BB3 respectively). Enhances glucose transport in obese and diabetic primary myocytes. Also stimulates NCI-H1299 lung cancer cell proliferation in v

[D-Phe12]-Bombesin acetate inhibits bombesin-stimulated secretion.

Bombesin acetate is a 14-amino acid peptide originally isolated from the skin of the European fire-bellied toad (Bombina bombina). It has two known homologs in mammals called neuromedin B and gastrin-releasing peptide.

RC-3095 TFA (RC-3095 (TFA)) is a bombesin gastrin-releasing peptide (BN GRP) antagonist with potential anticancer activity.

Litorin acetate, an amphibian bombesin peptide derivative, is an bombesin receptor agonist. It stimulates the contraction of smooth muscle, stimulates gastrin, gastric acid, and pancreatic secretion, and suppresses the nutriment in vivo.

Bombesin receptor antagonist

Broad spectrum neuropeptide inverse agonist and antagonist. Potent full inverse agonist for the ghrelin receptor (EC50 = 5.2 nM); diminishes constitutive ghrelin receptor signaling. Also antagonist at tachykinin, bradykinin, CCK and bombesin receptors. In

[Lys3]-Bombesin is a biologically active peptide used in PET (Positron Emission Tomography) imaging to identify GRPR (gastrin-releasing peptide receptor) positive prostate cancer. The compound, when conjugated with a corresponding monoclonal antibody, can selectively trigger CD64-dependent monocyte and neutrophil-mediated lysis in small cell carcinoma.

Mammalian bombesin-like peptide neurotransmitter that is an agonist for the gastrin-releasing peptide receptor (GRPR). GRP has been reported to activate GABAergic interneurons in the amygdala leading to increased GABA release and fear suppression in mice

Bombesin receptor antagonist that inhibits bombesin binding to rat brain with an IC50 value of 2 μM. Inhibits amylase release in vitro (IC50 = 4 μM) and attenuates bombesin-mediated suppression of food intake in vivo.

RC-3095 acetate is an antagonist of bombesin gastrin-releasing peptide receptor (GRPR). It exerts protective effects by reducing gastric oxidative injury in the arthritic mice.

BIM-26226, a gastrin-releasing peptide, serves as a potent and selective antagonist to the bombesin receptor, effectively inhibiting BN- or GRP-stimulated amylase release with IC50 values in the nanomolar range. It is utilized in cancer research [1] [2].

[D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P acetate ([D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P acetate (96736-12-8 free base)) is a broad spectrum neuropeptide inverse agonist and antagonist. Potent full inverse agonist for the ghrelin receptor (EC50 = 5.2 nM); diminishes constitutive ghrelin receptor signaling. Also antagonist at tachykinin, bradykinin, CCK and bombesin receptors. Induces apoptosis and inhibits cancer cell growth in vitro.

Potent bombesin receptor agonist (IC50 values are 0.26, 1.55 and 2.52 nM for BB1, BB2 and BB3 respectively). Enhances glucose transport in obese and diabetic primary myocytes. Also stimulates NCI-H1299 lung cancer cell proliferation in vitro.

Spantide antagonizes both bombesin & substance P. It is also tachykinin receptor antagonist.

BA 1 TFA acts as a potent agonist for the bombesin (BB) family of receptors, exhibiting high affinity binding to Bombesin receptor subtype-3 (BRS3), gastrin-releasing peptide receptor (GRPR), and neuromedin B receptor (NMBR), with IC50 values of 6, 0.4, and 2.5 nM, respectively [1].